Zacks Research Has Optimistic View of TSE:BHC Q2 Earnings

Bausch Health Companies Inc. (TSE:BHC) – Investment analysts at Zacks Research lifted their Q2 2025 earnings estimates for Bausch Health Companies in a report issued on Tuesday, March 11th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $1.52 per share for the quarter, up from their previous estimate of $1.49. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q3 2025 earnings at $1.67 EPS, Q1 2026 earnings at $1.59 EPS, Q4 2026 earnings at $1.80 EPS, FY2026 earnings at $6.84 EPS and FY2027 earnings at $8.21 EPS.

Bausch Health Companies Trading Up 2.2 %

Shares of BHC opened at C$9.96 on Thursday. The company’s fifty day moving average is C$10.39 and its 200 day moving average is C$10.57. Bausch Health Companies has a fifty-two week low of C$5.45 and a fifty-two week high of C$15.43. The stock has a market capitalization of C$2.59 billion, a PE ratio of -14.58, a P/E/G ratio of 0.21 and a beta of 0.77. The company has a debt-to-equity ratio of -1,831.94, a quick ratio of 0.58 and a current ratio of 1.19.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.